|
|
| Elan Announces New Organisation of Its Elan Pharmaceuticals Division |
DUBLIN, Ireland, Jan. 18 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN) ("Elan") today announced new appointments and the organisation structure of its Elan Pharmaceuticals division. Daniel G. Welch, who joined Elan Pharmaceuticals as its president in October 2000, announced that Lars Ekman M.D. PhD has now taken up his position of president, research and development, Elan Pharmaceuticals. Prior to joining Elan, Dr. Ekman was responsible for research and development at Schwarz Pharma AG and before this held senior research and development positions in Pharmacia. In this role Dr. Ekman assumes responsibility for the global research and development activities of Elan Pharmaceuticals. Robert S. Whitehead has been appointed to the position of president Americas, Elan Pharmaceuticals. Mr. Whitehead was formerly president and chief operating officer of Dura Pharmaceuticals, Inc ("Dura") the San Diego based specialty pharmaceutical company acquired by Elan in November 2000. Mr. Whitehead will assume responsibility for all commercial operations in the United States, Canada and Latin America including the US integration of Elan Pharmaceuticals, Dura and The Liposome Company, Inc into a single Elan Pharmaceuticals business unit. Also reporting to Mr, Welch as vice president, Europe and president & representative director, Elan Pharma K.K., Japan, will be Dr. Dai Rowley-Jones and Mr. Motohiro Ueda, respectively. Elan's Diagnostic businesses will now report directly to Mr. Welch under the management of Robert Flaherty, president, Athena Diagnostics, Inc. Donal J. Geaney, Elan's chairman and chief executive officer commented "I am delighted to welcome Lars and Bob to their new roles and am confident that under the leadership of Dan Welch, Elan Pharmaceuticals has a first class team of seasoned pharmaceutical executives to lead and grow our global pharmaceutical business". Elan Corporation, plc is a leading worldwide specialty pharmaceutical and drug delivery company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel. Elan is focused on the discovery, development and marketing of therapeutic products and services in neurology, pain management and oncology, and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies. Elan's shares trade on the New York, London and Dublin Stock Exchanges. This communication includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained herein. The forward-looking statements in this communication include statements about future operating results. Certain factors, including Elan's inability to successfully obtain approval milestones and other economic, competitive, business and/or regulatory factors affecting Elan's business generally, could cause actual results to differ materially from those described herein. More detailed information about these factors is set forth in Elan's filings with the Securities and Exchange Commission, including Elan's Annual Report on Form 20-F for the fiscal year ended December 31, 1999. Elan is under no obligation to (and expressly disclaims any obligation to) update or alter these forward-looking statements, whether as a result of new information, future events or otherwise.SOURCE Elan Corporation, plc
back to topRelated links:
Company News On-Call:
800-758-5804, ext. 231593
CONTACT:
Investors - U.S. - Jack Howarth,
212-407-5740, or 800-252-3526, or Investors - Europe - Emer
Reynolds, +353-1-709-4000, or +00800-28352600, or Media - Max
Gershenoff, 212-407-5740, or 800-252-3526, all of Elan
Corporation, plc
